Issues in the Design and Conductance of Clinical Trials

Animal and Translational Models for CNS Drug Discovery

Volumn , Issue , 2008, Pages 75-95

  McEvoy, Joseph P ^a   Freudenreich, Oliver ^b  

^a John Umstead Hospital   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882526704     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-373861-5.00003-5     Document Type: Chapter

References (35)

1. I. Kola and J. Landis (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3 711-715.
2. G. Lappin and R.C. Garner (2005) The use of accelerator mass spectrometry to obtain early human ADME/PK data. Expert Opin Drug Metab Toxicol 10 890-894.
3. B.H. Littman and S.A. Williams (2005) The ultimate model organism: Progress in experimental medicine. Nat Rev Drug Discov 4 631-638.
4. European Medicines Agency. (2004). Position paper on non-clinical safety studies to support clinical trials with a single microdose CPMP/SWP/2599/02/Rev1,. http://www.emea.eu.int/pdfs/human/swp/259902en.pdf
5. Center for Drug Evaluation and Research. (2005). Guidance for industry, investigators and reiewers: Exploratory IND studies. Draft guidance. US Department of Health and Human Services, Food and Drug Administration. Center for Drug Evaluation and Research, www.fda.gov/cder/guidance/6284dft.htm
6. E.M. Laska, D.F. Klein, P.W. Lavori, J. Levine and D.S. Robinson (1994) Design issues for the clinical evaluation of psychotropic drugs. R.F. Prein, D.S. Robinson (Eds) Clinical Evaluation of Psychotropic Drugs New York: Raven Press 29-68.
7. J. Posner (2000) The first administration of a new active substance to humans. A. Cohen, J. Posner (Eds) A Guide to Clinical Drug Research Norwell, MA: Kluver Academic Publishers 47-63.
8. R. Kartizinel, A.B. Lisook, B. Rullo, J.B. Severe and G. Spilker (1994) Clinical trial implementation. R.F. Prein, D.S. Robinson (Eds) Clinical Evaluation of Psychotropic Drugs New York: Raven Press 161-184.
9. R.A. Guarino (2000) Clinical research protocols. R.A. Guarino (Eds) New Drug Approval Process New York: Marcel Dekker 219-246.
10. W.M. Wooding (1994) Planning Pharmaceutical Clinical Trials. New York: John Wiley and Sons
11. S.B. Reele (1997) Decision points in human drug development. J. O’Grady, P.H. Joubert (Eds) Phase I/II Clinical Drug Trials Boca Raton, FL: CRC Press 67-80.
12. Chang, M., Chow, S.C., Pong, C. (2006 May). Adaptive design in clinical research: Issues, opportunities, and recommendations, J Biopharm Stat, 16(3)299–309, discussion 311-2
13. Gottlieb, S. (2006). Remarks, Conference on Adaptive Trial Design, http://www.fda.gov/oc/speeches/2006/trialdesign0710.html
14. N. Baber (2000) What does the investigator need to know about the drug? – The clinical investigators’ brochure. A. Cohen, J. Posner (Eds) A Guide to Clinical Drug Research Norwell, MA: Kluver Academic Publishers 19-45.
15. T.P. Laughren, J. Levine, J.G. Levine and W.L. Thompson (1994) Pre-marketing safety evaluation of psychotropic drugs. R.F. Prein, D.S. Robinson (Eds) Clinical Evaluation of Psychotropic Drugs New York: Raven Press 185-216.
16. M. Thomas (1997) Study design and assessment of wanted and unwanted drug effects in phase I/II trials. J. O’Grady, P.H. Joubert (Eds) Phase I/II Clinical Drug Trials Boca Raton, FL: CRC Press 157-169.
17. S. Heres, J. Davis, K. Maino, E. Jetzinger, W. Kissling and S. Leucht (2006) Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: An exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry 163 185-194.
18. R.H. Perlis, C.S. Perlis, Y. Wu, C. Hwang, M. Joseph and A.A. Nierenberg (2005) Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. Am J Psychiatry 162 1957-1960.
19. J.A. Lieberman, S. Stroup, J. McEvoy, M.S. Swartz, R.A. Rosenheck, D.O. Perkins, et al. (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New Engl J Med 353 1209-1223.
20. J.S. March, S.G. Silva, S. Compton, M. Shapiro, R. Califf and R. Krishnan (2005) The case for practical clinical trials in psychiatry. Am J Psychiatry 162 836-846.
21. G. Kemmler, M. Hummer, C. Widschwendter and W.W. Fleischhacker (2005) Dropout rates in placebo-controlled active-control clinical trials of antipsychotic drugs. Arch Gen Psychiatry 62 1305-1312.
22. L.M. Kassalow (2000) Statistical and data management. R.A. Guarino (Eds) New Drug Approval Process New York: Marcel Dekker 289-310.
23. J.G. Csernansky, R. Mahmoud and R. Brenner (2002) A comparison of risperdone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 346 16-22.
24. N. Schooler, J. Rabinowitz, M. Davidson, R. Emsley, P.D. Harvey, L. Kopala, et al. (2005) Risperdone and haloperidol in first-episode psychosis: A long-term randomized trial. Am J Psychiatry 162(5), 947-953.
25. H.C. Kraemer, J. Mintz, A. Noda, J. Tinklenberg and J.A. Yesavage (2006) Caution regarding the use of pilot studies to guide power calculations for study proposals. Arch Gen Psychiatry 63 484-489.
26. S.D. Halpern, J.H.T. Karlawish and J.A. Berlin (2002) The continuing unethical conduct of underpowered clinical trials. JAMA 288 358-362.
27. J.P. McEvoy and T. Barnes (2003) Guide to Assessment Scales in Schizophrenia. 2nd edition London: Science Press
28. S.R. Kay (1991) Positive and Negative Syndromes in Schizophrenia. New York: Brunner/Mazel
29. R.C. Young, J.T. Biggs, V.E. Ziegler, et al. (1978) A rating scale for mania: Reliability, validity and sensitivity. Br J Psychiatry 133 429-435.
30. J.P. McEvoy, G.E. Hogarty and S. Steingard (1991) Optimal dose of neuroleptic in acute schizophrenia. Archives of General Psychiatry 48 739-745.
31. K.A. Koback, J.M. Kane, M.E. Thase and A.A. Nierenberg (2007) Why do clinical trials fail? The problem of measurement error in clinical trials: Time to test new paradigms? J Clin Psychopharmacol 27 1-4.
32. C. Rowland (2004) Clinical trials seen shifting overseas. Int J Health Serv 34 555-556.
33. R.A. Rettig (2000) The industrialization of clinical research. Health Affairs 19 129-146.
34. P. Mirowski and R. Van Horn (2005) The contract research organization and the commercialization of scientific research. Soc Stud Sci 35 503-548.
35. M. Schuchmann (2007) Commercializing clinical trials – risks and benefits of the CRO boom. NEJM 357 1365-1368.